Lower urinary tract symptoms and its potential relation with late-onset hypogonadism

Aging Male

Volumn 11, Issue 2, 2008, Pages 51-55

  Pradidarcheep, Wisuit ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Aging; Androgen receptor; Nitric oxide; Penis; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN II; ENDOTHELIN; ESTROGEN RECEPTOR; NITRIC OXIDE; RHO KINASE; TESTOSTERONE;

AGING; CASTRATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; NONHUMAN; NOTE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

AGE OF ONSET; AGING; ANIMALS; HUMANS; HYPOGONADISM; INTRA-ABDOMINAL FAT; MALE; METABOLIC SYNDROME X; NITRIC OXIDE; RABBITS; RATS; RECEPTORS, ANDROGEN; TESTOSTERONE; URINARY TRACT; URINATION DISORDERS;

EID: 45849140201     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530801954026     Document Type: Note

References (52)

1. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004;159:390-397.
2. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7:288-292.
3. Rosen RC. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int 2006;97:29-33.
4. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97:23-28.
5. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice. Andrologia 2006;38:1-12.
6. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524-1527.
7. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-250.
8. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-293.
9. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005;96:67M-72M.
10. Schatzl G, Brossner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397-402.
11. Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health Survey. BJU Int 2007;100:321-326.
12. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis K, Smit E, Giovannucci E, Platz E. Serum sex steroid hormones and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007;69:708-713.
13. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
14. Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol 2007;4:161-166.
15. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995;14:87-96.
16. Salmi S, Santti R, Gustafsson JA, Makela S. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol 2001;166:674-677.
17. Keast JR. Plasticity of pelvic autonomic ganglia and urogenital innervation. Int Rev Cytol 2006;248:141-208.
18. Keast JR. Effects of testosterone on pelvic autonomic pathways: progress and pitfalls. J Auton Nerv Syst 2000;79:67-73.
19. Keast JR, Saunders RJ. Testosterone has potent, selective effects on the morphology of pelvic autonomic neurons which control the bladder, lower bowel and internal reproductive organs of the male rat. Neuroscience 1998;85:543-556.
20. Keast JR. The autonomic nerve supply of male sex organs - an important target of circulating androgens. Behav Brain Res 1999;105:81-92.
21. Purves-Tyson TD, Arshi MS, Handelsman DJ, Cheng Y, Keast JR. Androgen and estrogen receptor-mediated mechanisms of testosterone action in male rat pelvic autonomic ganglia. Neuroscience 2007;148:92-104.
22. Anderson GF, Navarro SP. The response of autonomic receptors to castration and testosterone in the urinary bladder of the rabbit. J Urol 1988;140:885-889.
23. Takyu S. Effects of testosterone on the autonomic receptor-mediated function in lower urinary tract from male rabbits. Nippon Hinyokika Gakkai Zasshi 1993;84:330-338.
24. Holmquist F, Persson K, Bodker A, Anderson KE. Some preand post-junctional effects of castration in rabbit isolated corpus cavernosum and urethra. J Urol 1994;152:1011-1016.
25. Juan YS, Onal B, Broadaway S, Cosgrove J, Leggett RE, Whitbeck C, De E, Sokol R, Levin RM. Effect of castration on male rabbit lower urinary tract tissue enzymes. Mol Cell Biochem 2007;301:227-233.
26. Nakazawa R, Tanaka M, Takahashi T, Kobayashi S, Iwamoto T. Effects of castration and testosterone administration on angiotensin II receptor mRNA expression and apoptosis-related proteins in rat urinary bladder. Endocr J 2007;54:211-219.
27. Peters SL, Schmidt M, Michel MC. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006;27:492-497.
28. Muto S, Yasuda M, Kamiyama Y, Ide H, Horie S. Testosterone decreased urinary-frequency in nNOS-deficient mice. Int J Androl 2007;31:67-70.
29. Ehren I, Adolfsson J, Wiklund NP. Nitric oxide synthase activity in the human urogenital tract. Urol Res 1994;22:287-290.
30. Smet PJ, Jonavicius J, Marshall VR, de Vente J. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996;71:337-348.
31. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001;29:388-392.
32. Werkstrom V, Svensson A, Andersson KE, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006;98:414-423.
33. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinol 2007;148:1019-1029.
34. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL, Chang TS. The effect of androgen on nitric oxide synthase in the male eproductive tract of the rat. Fertil Steril 1995;63:1101-1107.
35. Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001;19:344-350.
36. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836-839.
37. Montorsi F, Corbin J, Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med 2004;1:322-336.
38. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 2006;50:1194-1207.
39. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
40. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
41. McVary KT, Monnig W, Camps JL,Jr.,Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177:1071-1077.
42. Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003;5:33-36.
43. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-1868.
44. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003;144:5081-5088.
45. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005;26:242-248.
46. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, Huang YH, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24:381-387.
47. Schultheiss D, Badalyan R, Pilatz A, Gabouev AI, Schlote N, Wefer J, von Wasielewski R, Mertsching H, Sohn M, Stief CG, et al. Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 2003;21:320-324.
48. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-2263.
49. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006;50:940-947.
50. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006;8:3-9.
51. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-592.
52. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006;3:727-735.